TY - CHAP M1 - Book, Section TI - Skin Cancer in the Organ Transplant Patient A1 - Jenkins, Sasha A1 - Cotes, Maren A1 - Zwald, Fiona A2 - Avram, Marc R. A2 - Avram, Mathew M. A2 - Ratner, Désirée Y1 - 2015 N1 - T2 - Procedural Dermatology AB - Advances in the management of solid organ transplantation recipients (OTR) have led to improved overall survival. However, patients face many consequences of being on long-term immunosuppression, including an increased risk of developing premalignant and malignant skin cancers. This is likely to pose an increasing challenge to dermatologists, as the number of patients receiving a solid organ transplant continues to grow and the life expectancy of these patients continues to increase. Skin cancers are the most common malignancy posttransplantation, comprising almost 40% of posttransplant malignancies, and tend to behave more aggressively than in nontransplant patients.1 The increased risk of skin cancer impacts patient morbidity and quality of life post transplantation, and management of such cases places a significant burden on diminishing health care resources. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/10/05 UR - dermatology.mhmedical.com/content.aspx?aid=1175094650 ER -